Benign Prostate Hyperplasia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male aged 50-80; 2. IPSS>12, Qmax = 15mL/s (VV>150mL); 3. Prostate volume 30-80mL (transrectal ultrasound); 4. Patients with lower urinary tract symptoms and diagnosed with BPH who plan to undergo TURP surgery; 5. Voluntarily participate in clinical trials and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with concurrent bladder stones; 2. Difficulty in inserting instruments for urethral stricture (urethral conditions may hinder the insertion of bladder endoscope F20 and above); 3. Neurogenic lower urinary tract symptoms; 4. Prostate specific antigen exceeds the normal range and prostate cancer cannot be ruled out; 5. Patients with bladder cancer and other urothelial cancer; 6. Patients who have previously undergone BPH or urethral surgery; 7. Severe cardiovascular disease, lung disease, or other systemic diseases that cannot tolerate surgery; 8. Individuals who participate in other clinical trials related to prostate hyperplasia within the first three months of enrollment; 9. Patients who are unwilling to accept clinical research protocols.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International prostate symptom score, IPSS;Qmax; | — |
Secondary
| Measure | Time frame |
|---|---|
| QoL;PVR;VV;Operation time;IIEF-5;MSHQ-EjD;ICIQ-MLUTS-Urinary Symptoms;ICIQ-MLUTS-Sexual Function;Hemoglobin;Serum sodium;Complication;QoR VAS;Postoperative bladder irrigation time;Postoperative indwelling catheterization time;Postoperative hospitalization time;Postoperative bladder irrigation fluid volume; | — |
Countries
China
Contacts
The First Affiliated Hospital of Xi'an Jiaotong University